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AbstractHematological malignancies are broadly divided into myeloid and lymphoid neo-
plasms, reflecting the twomajor cellular lineages of the hematopoietic system. It is generally
rare for hematological malignancies to spontaneously progress with a switch from myeloid
to lymphoid lineage. We describe the exceptional case of a patient who sequentially devel-
oped myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and B-
cell acute lymphoblastic leukemia (B-ALL), as well as our investigation into the underlying
pathogenesis. Using whole-exome sequencing (WES) performed on sorted CMML and B-
ALL cell fractions, we identified both common and unique potential driver mutations, sug-
gesting a branching clonal evolution giving rise to both diseases. Interestingly, we also
identified a germline variant in the cancer susceptibility gene CHEK2. We validated that
this variant (c.475T>C; p.Y159H), located in the forkhead-associated (FHA) domain, im-
pairs its capacity to bind BRCA1 in cellulo. This unique case provides novel insight into
the genetics of complex hematological diseases and highlights the possibility that such pa-
tients may carry inherited predispositions.
[Supplemental material is available for this article.]
INTRODUCTION
Myelodysplastic syndromes (MDSs) are a group of hematological malignancies character-
ized by ineffective hematopoiesis, chronic cytopenias, and dysplastic morphological
changes in bone marrow cells (Cazzola 2020). MDS is associated with a wide variety of chro-
mosomal and genetic abnormalities affecting processes such as epigenetic regulation, RNA
splicing, transcription, cell cycle control, and DNA repair (Ogawa 2019). Although the
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severity and rate of progression of MDS is highly variable among individuals, transformation
to acute myeloid leukemia (AML) is a well-described component of the natural history of the
disease and occurs in ∼30% of MDS patients (Porwit and Saft 2011). Evolution of MDS to
other leukemias, such as chronic myelomonocytic leukemia (CMML) and B-cell acute lym-
phoblastic leukemia (B-ALL), has been described in case reports but is considered exceed-
ingly rare (Disperati et al. 2006; Niscola et al. 2013; Martins et al. 2021).
Although the mechanisms underlying MDS to ALL transformation are still poorly under-
stood, it has been proposed that this results from the stepwise acquisition of genetic or epi-
genetic alterations within a self-renewing multipotent hematopoietic stem or early
progenitor cell (Disperati et al. 2006; Martins et al. 2021). MDS-specific cytogenetic changes
can be identified within the lymphoid compartment of some MDS patients, providing evi-
dence for clonal lymphoid output in at least a subset of MDS cases (van Lom et al. 1995;
Nilsson et al. 2000). Additionally, blood cancer development may originate within a preleu-
kemic hematopoietic stem cell (HSC) pool, because cancer-associated mutations can be
found in the normal blood cells of healthy individuals (Zink et al. 2017) and patients with
AML (Jan et al. 2012) or lymphoma (Quivoron et al. 2011). From this premalignant reservoir,
it is possible that branching evolution may occur. Overall, characterizing the genetic evolu-
tion of patients who develop multiple hematological malignancies may provide additional
insight into their pathogenesis and guide therapy.
In this study, we leveraged fluorescence-activated cell sorting (FACS) and whole-exome
sequencing (WES) to elucidate the genetic underpinnings of an exceptionally rare case of a
patient who underwent transformation from MDS to CMML, followed by a terminal B-ALL
blast phase. We identified suspected driver mutations shared between themyeloid and lym-
phoid populations, including NRAS, TET2, EZH2, and ZRSR2, supporting a common clonal
origin. Other mutations were unique to the CMML (ASXL1) or B-ALL (BRD2) clones. In addi-
tion, we found a germline variant of unknown significance (VUS) in the checkpoint kinase 2
(CHEK2) tumor-suppressor gene affecting a critical protein domain. CHEK2 is a cancer sus-
ceptibility gene that has been associated with MDS (Janiszewska et al. 2018). We performed
functional validation on this mutant CHK2 protein and demonstrated impaired binding to
downstream BRCA1, suggesting this variant may be cancer-predisposing.
RESULTS
Case Presentation and Family History
A 56-year-old male was referred to the hematology clinic for an isolated finding of severe but
asymptomatic neutropenia. He did not have any personal history of cancer or prior hemato-
logic disease. However, his mother had been diagnosed with essential thrombocytosis (ET)
and his father with colorectal cancer. He also had a brother with an unspecified malignancy.
A bone marrow biopsy was consistent with a diagnosis of MDS with multilineage dysplasia
(MDS-MLD) by World Health Organization (WHO) 2016 criteria (Swerdlow et al. 2017). His
International Prognostic Scoring System (IPSS) risk score was low and the karyotype showed
-Y in all metaphases. He was managed with observation alone for 10 years until he eventually
developed worsening anemia, which was treated with recombinant erythropoietin (EPO).
Following an initial response, the anemia became refractory to EPO, and he developed pro-
gressive neutrophilia and monocytosis. Repeat bone marrow examination was consistent
with transformation to CMML without blast count elevation (WHO 2016 criteria, intermedi-
ate-1 IPSS score) (Swerdlow et al. 2017). The karyotype remained unchanged (-Y). The pa-
tient was started on lenalidomide 10 mg daily. This resulted in control of white blood cell
counts, although he remained dependent on red blood cell transfusions. Following 2 years
of stability, he experienced abrupt onset leukocytosis. Examination of the blood smear
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revealed abundant blasts. Bone marrow examination (morphology and flow cytometry) now
showed a B-ALL clone in addition to the background CMML. The karyotypewas unchanged.
He was admitted to the hospital and treated with a five-drug induction consisting of predni-
sone, daunorubicin, vincristine, cyclophosphamide, and L-asparaginase. This was complicat-
ed by severe invasive fungal infection (fusarium species), liver toxicity, and prolonged
hospital admission. He was not deemed fit for further intensive combination chemotherapy
following these events. Roughly 8 months after the induction regimen, he experienced florid
relapse of both the CMML and B-ALL clones. It was at this time point that a sample was col-
lected for WES. Attempts were made to control the disease with several lines of therapy, in-
cluding vincristine monotherapy, mitoxantrone monotherapy, and inotuzumab ozogamicin.
Responses were brief. Eventually, both leukemias became refractory to therapy andmultiple
organ failure ensued. Comfort care was instituted. The patient died 14 years after the initial
MDS diagnosis.
Genomic Analyses
We used FACS to separate the peripheral blood sample into B lymphoid (CD19+/CD33−)
and myelomonocytic (CD19−/CD33+) populations. We extracted genomic DNA from these
two fractions and a buccal swab. We performed WES on these three samples. Following the
bioinformatics analysis (see Methods), we identified 11 potential driver mutations meeting
retention criteria. These variants (Table 1) included six nonsynonymous single-nucleotide
variants (SNVs), four indels, and one stop-gain. Some variants were shared across all three
samples (buccal swab, B lymphoid, myelomonocytic), suggesting a germline origin.
Others were unique to one or both sorted cellular fractions, indicating somatic mutation
events. The buccal swab yielded lower DNA quantity, and WES performed on this sample
had 12.72× mean coverage. Therefore, we confirmed the presence or absence of each var-
iant reported in Table 1 for all samples using Sanger sequencing as an orthogonal validation
method.
To evaluate our samples for allelic imbalance (AI), we used the web-based application
ExomeAI (Nadaf et al. 2015). This analysis revealed a large AI in the long arm of
Chromosome 4 (Chr 4q) in both the CMML and B-ALL samples. This finding is consistent
with the identification of a frameshift deletion in TET2 (located on Chr 4q) with a variant allele
frequency (VAF) of 1.0 in both tumor samples. In addition, we also identified a large AI on
Chromosome 16q unique to the B-ALL sample.
Functional Analyses
The tumor-suppressor CHEK2 c.475T>C variant identified using WES was of interest to us
given its possible role as a cancer-predisposing mutation. We confirmed the presence of this
mutation by Sanger sequencing of the buccal swab and myelomonocytic and B-lymphoid
samples. We also found this mutation in nonmalignant T cells sorted from this patient
(Supplemental Fig. S1). This strongly suggested a germline origin for this variant. The result-
ing amino acid change (CHK2 Y159H) is only two positions away from the known pathogenic
variant I157T (Fig. 1), which affects the forkhead-associated (FHA) domain and impairs bind-
ing of downstream effectors such as BRCA1, p53, and CDC25 family proteins (Li et al. 2002).
We hypothesized that the Y159H variant could have a similar deleterious effect on the FHA
domain as it was predicted as pathogenic by all six in silico prediction tools that we used (see
Methods). Currently, ClinVar classifies Y159H as being of uncertain significance, in part due
to lack of growth perturbation in a yeast-based functional assay (Delimitsou et al. 2019).
Similarly, the variant is considered a VUS on VarSome based on the American College of
Medical Genetics and Genomics (ACMG) classification (Richards et al. 2015; Kopanos
et al. 2019).
WES applied to a case of concomitant CMML/B-ALL
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To test our hypothesis, we took advantage of a single-cell assay in which the association
of two proteins can be assessed at an integrated LacO array by tethering an mCherry-LacR-
tagged version of any prey of interest (Fig. 2). This LacO/LacR system has been successfully
used to characterize the association between BRCA1 and PALB2 (Orthwein et al. 2015) and
to determine the impact of a pathogenic RAD51D variant on its association to XRCC2 (Rivera
et al. 2017). Using this approach, we first confirmed that an mCherry-LacR-tagged version of
CHK2 can recruit endogenous BRCA1 to the LacO array (Fig. 2). We then evaluated the
impact of the Y159H variant on the CHK2–BRCA1 association. As comparators, we used
wild-type (WT) CHK2 and two previously described loss-of-function variants (I157T and
H143Y). The I157T variant disrupts the FHA domain, and the H143Y variant produces a high-
ly unstable protein (Bell et al. 2007, Li et al. 2002). Our results showed that the Y159H
mutation drastically impairs CHK2 association to BRCA1 similarly to the other two loss-of-
function variants, suggesting that it significantly disrupts the FHA domain (Fig. 2). These
data support the categorization of CHK2 Y159H as likely pathogenic.
DISCUSSION
In this study, we leveraged FACS andWES to elucidate the genetic underpinnings of a highly
unusual case of transformation from a chronic myeloid malignancy (MDS, CMML) to an ag-
gressive lymphoid malignancy (B-ALL). We identified 11 putative driver mutations with var-
ious distributions between the buccal swab and malignant samples that allowed us to
propose a model of branching clonal evolution and identify a possible inherited
predisposition.
Four variants (CDKN1A, BMPR1A, FOXA2, CHEK2) were shared across the buccal swab,
CMML clone, and B-ALL clone, suggesting these were germline mutations. Although
CDKN1A, BMPR1A, and FOXA2 have all been implicated in human malignancies to various
degrees (Halmos et al. 2004; Calva-Cerqueira et al. 2009; Kreis et al. 2019), there is little ev-
idence to suggest these were pathogenic in this specific case beyond in silico predictions.
CHEK2 demonstrates a broader spectrum of associated malignancies and is considered a
cancer susceptibility gene with a low-to-moderate penetrance (Stolarova et al. 2020). It en-
codes the protein CHK2, which regulates the DNA damage response by phosphorylating
Figure 1. Schematic representation of the CHK2 protein and its major domains. A selection of five pathogenic
mutations described in the literature is depicted in red. The position of the CHK2 Y159H variant described in
this report is shown in black, highlighting its proximity to the pathogenic I157T variant. The SCD region is the
site of phosphorylation and activation by ATM. The FHA domain is critical for the binding of downstream pro-
teins such as BRCA1, p53, and CDC25A (Li et al. 2002). Figure redrawn using data from Cai et al. (2009) and
Stolarova et al. (2020). (ATM) Ataxia-telangiectasia mutated, (BRCA1) breast cancer type 1 susceptibility pro-
tein, (CDC25A) M-phase inducer phosphatase 1, (FHA) forkhead-associated domain, (KD) kinase domain,
(p53) cellular tumor antigen p53, (SCD) serine-glutamine/threonine-glutamine cluster domain.
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and activating BRCA1, promoting the homologous recombination repair pathway. CHK2
also appears to be implicated in the control of apoptosis, senescence, and p53-mediated
cell cycle arrest, although it does not appear to be indispensable for the latter (Antoni
et al. 2007). We suspected a possible pathogenic role for CHEK2 c.475T>C (Y159H)
because of in silico predictions and proximity to the known I157T FHA variant, which impairs
BRCA1, p53, and CDC25 binding, thus potentially promoting tumorigenesis (Li et al. 2002).
Notably, CHEK2 I157T has been identified as a risk factor for the development of MDS and
ET in Polish populations (Janiszewska et al. 2012; Janiszewska et al. 2018). Recently, it was
also shown to increase the risk of myeloproliferative neoplasms by promoting self-renewal
of HSCs (Bao et al. 2020). Using a LacO–LacR system, we demonstrated that the Y159H var-
iant behaves similarly to I157T in terms of impaired binding to BRCA1. This suggests that the
variant we identified in this patient may possibly be cancer-predisposing and warrant further
study. Prior to this new data, we considered the Y159H variant as meeting the ACMG criteria
PM1 (located in a critical functional domain), PM2 (absent in healthy controls), and PP3 (in
silico predictions), giving an overall classification of VUS (2 moderate, 1 supporting criteria)
(Richards et al. 2015). Our new functional data would qualify as an additional supporting cri-
terion (PS3_supporting) as per recent Clinical Genome Resource (ClinGen) recommenda-
tions (Brnich et al. 2019). If our findings can be reproduced by other laboratories, this has
the potential to reclassify Y159H as likely pathogenic as per ACMG criteria (two moderate,
two supporting) (Richards et al. 2015).
BA
C
Figure 2. CHK2–BRCA1 colocalization assay. (A) Schematic representation of the experimental assay (redrawn
from Orthwein et al. 2015). (B) Representative confocal microscopy images. The location of the LacO array
(white square) is identified by the accumulation of mCherry signal. Colocalization of BRCA1 and CHK2 is as-
sessed at the mCherry focus by measuring the AF-647 signal, representing endogenous BRCA1. (C )
Relative AF-647 signal (representing BRCA1) at the mCherry focus for the various CHK2 variants studied.
The control (Ctrl) is an mCherry-LacR construct lacking CHK2. Statistical significance was assessed using
Dunnett’s multiple comparisons test using wild-type CHK2 as the comparator. (∗) P≤ 0.05, (∗∗) P≤ 0.01.
(AF-647) Alexa Fluor 647, (BRCA1) breast cancer type 1 susceptibility protein, (CHK2) checkpoint kinase 2,
(WT) wild type.
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We identified other variants that were absent from the buccal swab but shared between
the CMML and B-ALL clones. This suggests that these mutations were somatic and likely
arose earlier in the disease course, probably at the MDS or CMML stage, prior to the emer-
gence of the B-ALL clone. Of these variants, three consisted of highly typical MDSmutations
(TET2, EZH2, ZRSR2). These genes regulate DNA methylation, histone modification, and
RNA splicing, respectively, and are implicated in the pathophysiology of MDS (Ogawa
2019). TET2 mutations are also common in clonal hematopoiesis (CH), which may precede
MDS (Jaiswal et al. 2014). An activating NRAS mutation was identified in both leukemic
clones. This variant affects the G12 hotspot of the NRAS protein and leads to aberrant cel-
lular proliferation (Prior et al. 2012). We hypothesize that this mutation may have been ac-
quired at the MDS to CMML transition when the disease began to behave more
aggressively. As we did not have access to samples earlier in the disease course, the attribu-
tion of a mutation to the MDS or CMML stage is based on the knowledge of common driver
mutations in these entities. The identification of a somatic mutation in the circadian rhythm
regulator CLOCK was intriguing. Circadian disruption linked to night-shift work has been as-
sociated with increased risk of a wide range of human malignancies (Fu and Kettner 2013).
The circadian clock is thought to act as a tumor suppressor by modulating cellular prolifer-
ation, apoptosis, and the immune system (Fu and Lee 2003). In microsatellite unstable colo-
rectal cancers, somatic loss-of-function CLOCK mutations appear to be very common and
may promote tumorigenesis via dysregulation of DNA damage response genes such as
CDKN1A and RAD50, as suggested by a chromatin immunoprecipitation sequencing
(ChIP-seq) approach (Alhopuro et al. 2010). The role of CLOCKmutations in MDS and other
hematologic malignancies remains to be defined.
Two variants were exclusively identified in a single clone. These included a frameshift
deletion in ASXL1 for the CMML clone and a nonframeshift insertion in BRD2 in the B-ALL
clone. Truncating exon 12 mutations in ASXL1, such as the one identified in this patient,
are commonly described in myeloid malignancies but are particularly frequent in CMML
(∼45% of cases) (Gelsi-Boyer et al. 2012). These mutations cause loss of ASXL1 protein
and aberrant chromatin remodeling, leading to overexpression of oncogenes such as
HOXA genes and activation of the PI3K/AKT pathway via suppression of PTEN (Abdel-
Wahab et al. 2012; Cao et al. 2020). Interestingly, ASXL1 mutations seem to cooperate
with NRAS G12D in CMML (Abdel-Wahab et al. 2012), as was observed in our patient.
ASXL1 mutations are generally regarded as early events in leukemogenesis (Fujino and
Kitamura 2020). However, in our case, the ASXL1mutation was only seen in the CMML clone
and not the B-ALL clone. It is possible that the subclone responsible for the B-ALL transfor-
mation simply did not carry theASXL1 variant or that the variant was lost in the B-ALL clone as
a result of lack of selective advantage. The B-ALL clone could either have arisen from the
CMML clone or from a shared progenitor. The only retained mutation found to be unique
to the B-ALL clone in our analysis was a 3-bp insertion in the gene BRD2 resulting in the
in-frame addition of a single amino acid. This gene encodes BRD2, a BET protein family
member involved in regulating transcription (French 2016). Little is known on the role of
BRD2 in human cancers. However, overexpression of BRD2 induces B-cell lymphoma/leuke-
mia in murine models (Greenwald et al. 2004). The insertion that we identified falls within the
functionally important first bromodomain (BD1); however, it is unclear how this could lead to
gain of function of the protein (Yu et al. 2015). Overall, we believe that this mutation is un-
likely to be solely responsible for the B-ALL transformation in this patient. Because we did
not obtain excellent coverage with WES, it is possible that other driver mutations were
missed in the B-ALL clone. In addition, our study design could not evaluate epigenetic
changes, which are highly relevant to cancer biology (Sharma et al. 2010). It is also possible
additional karyotypic abnormalities beyond -Ymay have beenmissed in the B-ALL clone giv-
en the imperfect sensitivity of G-band karyotyping.
WES applied to a case of concomitant CMML/B-ALL
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Overall, our study identified a common clonal origin and provided evidence for the
sequential acquisition of driver mutations in a patient with complex hematological disease
progressing through three stages (MDS, CMML, B-ALL). This allowed us to construct a puta-
tive sequence of mutation acquisition (Fig. 3). We also validated the likely pathogenic effects
of a germlineCHEK2 variant (CHK2 Y159H), which possibly represented a cancer-predispos-
ing condition in this case.
METHODS
Flow Cytometry and Cell Sorting
We processed the patient blood sample using Ficoll density gradient centrifugation to ob-
tain peripheral blood mononuclear cells (PBMCs). The PBMCs were cryopreserved at −80°C
until recovery for processing. After thawing, we stained the PBMCs using CD19-APC
(eBioscience, clone HIB19, 17-0199-41) and CD33-FITC (eBioscience, clone WM53, 11-
0338-41). These cell surface markers were chosen based on the clinical flow cytometry pan-
els performed on this patient that showed the B-ALL clone was CD19+/CD33− and the
CMML clone was CD19−/CD33+. We used a BD FACSAria Fusion cell sorter to isolate the
B-lymphoid fraction (CD19+/CD33−) and the myelomonocytic fraction (CD19−/CD33+). To
isolate T cells for CHEK2 variant detection, we added CD3-BV786 (BD Biosciences, clone
SK7, 563800) and sorted the CD19−/CD33−/CD3+ fraction. The cell sorting strategy is out-
lined in Supplemental Figure S2. A postsorting purity check revealed >99% purity for the tar-
get populations.
Whole-Exome Sequencing
We extracted genomic DNA from the sorted cell populations as well as a concomitantly col-
lected buccal swab using the DNeasy Blood and Tissue Kit (QIAGEN 69506). WES was per-
formed on the B-lymphoid, myelomonocytic, and buccal swab DNA samples by Novogene
Co. The Agilent SureSelect Human All Exon kit (Agilent Technologies) was used to generate
the sequencing libraries. Sequencingwas performed on an Illumina platform (150-bp paired-
Figure 3. Putative sequence of clonal evolution in the presented case. (B-ALL) B-cell acute lymphoblastic leu-
kemia, (CMML) chronic myelomonocytic leukemia, (MDS) myelodysplastic syndrome.
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end reads). Clean reads were aligned to the human reference genome GRCh37/hg19 using
BWA-MEM (Li and Durbin 2009). Sequencing metrics are presented in Table 2. For the buc-
cal swab sample, germline variants were called using HaplotypeCaller (GATK, Broad
Institute) and hard-filtered using the following parameters: QD<2.0, FS>60.0, MQ<
40.0, HaplotypeScore>13.0, MappingQualityRankSum<−12.5, ReadPosRankSum<−8.0.
We used Mutect2 with a panel of normals (PON) to call somatic variants in the B-lymphoid
and myelomonocytic fractions, followed by filtering using FilterMutectCalls (GATK, Broad
Institute). Annotation was performed using ANNOVAR (Wang et al. 2010). We further refined
the list of variants by excluding synonymous SNVs, noncoding region variants, variants iden-
tified at a rate >0.01% in population databases (1000G, ExAC, ESP6500si, gnomAD), and
known benign variants on ClinVar. Finally, we identified likely driver mutations using
Cancer Genome Interpreter (Tamborero et al. 2018) to obtain the final list presented in
Table 1. In parallel, we performed a pathogenicity assessment as previously described (de
Kock et al. 2019). Briefly, frameshift and nonsense variants were classified as pathogenic.
Otherwise, nonsynonymous SNVs were classified as either pathogenic, likely pathogenic,
VUS, or benign using a score derived from a combination of six in silico tools (SIFT,
PolyPhen-2, M-CAP, FATHMM, PROVEAN, CADD). We did not retain any predicted benign
variants in the curated list. We retained only variants with at least 10× coverage in at least
one of the samples. We used Sanger sequencing to validate all variants reported in Table
1. The ExomeAI analysis for AI assessment was performed using the web-based application
(http://genomequebec.mcgill.ca/exomeai) with the default settings (Nadaf et al. 2015).
Functional Validation of the CHK2 Y159H Variant
To evaluate the effect of the CHK2 Y159H variant on BRCA1 binding, we used the previously
described LacO–LacR system (Tang et al. 2013; Orthwein et al. 2015). We obtained the
CHEK2 open reading frame (ORF) vector from the ORFeome Collaboration provided by
the McGill Platform for Cellular Perturbation of the Goodman Cancer Research Centre
and Biochemistry at McGill University. We generated the Y159H mutant variant using the
QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies). We also generated
I157T and H143Y mutants (known dysfunctional variants) for comparison (Bell et al. 2007).
The oligonucleotides used in the QuikChange protocol are detailed in Supplemental
Table S1. Gateway cloning technology (Invitrogen) was used to insert the CHEK2 mutant
and WT vectors into a pDEST-mCherry-LacR vector. We confirmed the expected sequence
and mutations in the final constructs using Sanger sequencing.
U2OS cells containing a stable integration of a Lac operator repeat sequence (U2OS-
LacO) were plated onto #1.5 coverslips in a 12-well plate. We transfected the U2OS-LacO
cells at 60% confluency with 1 µg of each mCherry-LacR-CHEK2 construct. The coverslips
were then rinsed twice with PBS, fixed with PBS+2% paraformaldehyde (Thermofisher) for
20 min at room temperature (RT), washed twice again with PBS, and then followed by a
20-min permeabilization in PBS+0.3% Triton-100 solution at RT. The coverslips were








% of target covered with
at least 10×
B lymphoid 47,361,768 25.10 99.88 79.17× 97.0
Myeloid 63,717,732 25.45 99.92 97.19× 97.8
Buccal
swab
6,849,050 23.71 99.89 12.72× 49.8
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washed twice with PBS and blocked for 1 h in PBS+5% BSA+0.1% Triton-100 (PBSA-T) at
RT. These were then incubated for 1 h with a 1:400 dilution of rabbit anti-BRCA1 primary an-
tibody (EMD Millipore 07-434) at RT, washed twice with PBS, and incubated with secondary
antibody (goat anti-rabbit Alexa Fluor 647, Thermofisher A-21244) in PBSA-T for 1 h at RT.
The coverslips were washed twice in PBS, washed once in ddH2O, and then mounted with
Fluoromount-G (Thermofisher). Images were acquired with a LSM 800 confocal microscope
(Carl Zeiss AG) and analyzed as previously described (Findlay et al. 2018). The colocalization
of BRCA1 (AF647 signal) with WT and variant CHK2 was measured at the LacO repeat array
(Fig. 2B) and quantified by calculating the mean fluorescence intensity (MFI) of AF647 at the
mCherry focus divided by theMFI of AF647 in the background region of the nucleus (relative
fluorescence). Two biological replicates were performed for each variant, and a minimum of
25 cells were evaluated per replicate. Statistical significance was assessed using ordinary
one-way ANOVAwith Dunnett’s multiple comparisons test in GraphPad Prism software (ver-
sion 9.0.0) using the WT CHK2 as a control (Fig. 2C).
ADDITIONAL INFORMATION
Data Deposition and Access
The raw WES data is available on the European Genome-Phenome Archive (EGA) under
study accession ID #EGAS00001005117. The CHEK2 variant was submitted to ClinVar
(https://www.ncbi.nlm.nih.gov/clinvar/) and can be found under the accession number
SCV001593269.
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